Introduce new products including Precise Liquid and FirstGene
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Feb 2023
- Due
- 31 Dec 2023
- Checked
- 2 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We plan to introduce a number of new products in the second half of 2023, including Precise Liquid and FirstGene.”
What we found
Evidence strength A What the grades mean
The company did not introduce FirstGene or Precise Liquid by the end of 2023; subsequent filings indicate these products were still planned for future launch or were acquired later.
-
A Myriad Genetics Inc. 8-K filed 2024-02-27
“As we look beyond 2024, we are excited about the new product launches we expect in the second half of 2024 or early 2025 including, Foresight Universal Plus, FirstGene, Precise Tumor (relaunch) and Liquid” ✓ confirmed on the page
Market reaction: the shares moved -9.1% against the S&P 500 over the three sessions around the disclosure (26 Feb 2024 to 29 Feb 2024). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Introduce
- Deliverable
- Precise Liquid and FirstGene
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Myriad Genetics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-MYGN-003920 · Corrections policy